AstraZeneca Lifts Outlook, Plans $3.5B US Investment

KEY TAKEAWAYS British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026. AstraZeneca plans to invest $3.5 billion in capital to expand its U.S. research and manufacturing footprint, including $2 billion to create "more than a thousand new, high-skilled jobs contributing to the growth of the U.S. economy," it said. The pharma giant also reported higher-than-estim ...